Business
Daré Bioscience Reports Third Quarter 2020 Financial Results and Provides Company Update
Conference Call Today at 4:30 p.m. Eastern Time SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health
About this update from Dare Bioscience, Inc.
[{"type":"text","content":"Conference Call Today at 4:30 p.m. Eastern Time\nSAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the third quarter ended September 30, 2020 and provided a company update.\n “We made great progress toward our strategic and operational objectives during the third quarter. I’m proud to report that despite this year’s challenging operating environment, our team continued to execute efficiently, allowing us to maintain our progress toward our anticipated milestones for 2020 and 2021,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “The completion of the DARE-BVFREE pivotal study of DARE-BV1 for the treatment of bacterial vaginosis will be an important milestone for Daré. We expect to report topline results from this Phase 3 study before the end of 2020 and to submit a new drug application to the FDA in the first half of 2021 if the study is successful. It has been roughly two years since we licensed the rights to the DARE-BV1 program, and the rapid pace at which we have advanced its development is evidence of the strength of the entire Daré team.” “The DARE-BVFREE topline data read-out in Q4 2020 represents the first in a series of anticipated milestones for our later-stage clinical-stage product candidates,” said David Friend, PhD, Chief Scientific Officer of Daré Bioscience. “In 2021, we are planning to initiate a Phase 2b study of Sildenafil Cream, 3.6%, our candidate for female sexual arousal disorder, the sexual dysfunction condition in women most analogous to erectile dysfunction in men, and look forward to reporting topline data from this study by the end of 2021. FSAD is a highly pervasive condition for which no FDA-approved product exists. A safe, effective and convenient option for women is long overdue, and we hope to be able to provide such a solution. In 2021, we also look forward to advancing Ovaprene®, our investigational hormone-free, monthly contraceptive, into a pivotal study that we expect, if successful, to support a premarket approval submission to the FDA.” U.S. commercial rights for Ovaprene are subject to a license agreement with Bayer, which was announced earlier this year. Recent Business Highlights DARE-LARC1: Received approximately $0.9 million in funding that remained under ...